Is it the heart or the mind—and which psychotropic is safe to prescribe? This update reviews QTc risk, orthostasis, and metabolic effects across antidepressants and antipsychotics in cardiac patients.

The FDA’s 2004 black-box warning aimed to boost suicidality monitoring in youth on antidepressants. Two decades and thousands of prescriptions later, did it work—or did it quietly reshape treatment patterns in unintended ways?

We take a close look at the new FDA panel on antidepressants in pregnancy, treatment guidelines for postpartum psychosis, and the role of zuranolone.

Investigators reveal measurable antidepressant effects of Vitamin D but limited benefits for anxiety, quality of life, or depression remission.

Two new and related studies compare treatments for resistant depression, shedding light on how different strategies stack up after medication trials fail.

When patients ask about weight changes with antidepressants, providing guidance can be challenging. While bupropion is often considered weight-neutral and paroxetine an offender, how do other common antidepressants compare?

It’s not just finding the antidepressant—dose, duration, and augmentation strategies matter.